Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sophie Callies

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II studyRonald Natale, Fiona Blackhall, Dariusz Kowalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyDenis C Talbot, Malcolm Ranson, Joanna Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III TrialsJosep M Llovet, Amit G Singal, Augusto Villanueva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2011
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumorsStijn L W Koolen, Petronella O Witteveen, Robert S Jansen, et al.
European Urology|November 20, 2013
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancerPaweł Wiechno, Bradley G Somer, Begoña Mellado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate CancerChristopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2014
Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II studyRonald Natale, Fiona Blackhall, Dariusz Kowalski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2010
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyDenis C Talbot, Malcolm Ranson, Joanna Davies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III TrialsJosep M Llovet, Amit G Singal, Augusto Villanueva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2011
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumorsStijn L W Koolen, Petronella O Witteveen, Robert S Jansen, et al.
European Urology|November 20, 2013
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancerPaweł Wiechno, Bradley G Somer, Begoña Mellado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 1, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate CancerChristopher J Sweeney, Ivor J Percent, Sunil Babu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced CancerTimothy A Yap, Maria Vieito, Capucine Baldini, et al.
Pageof 3